Thyrocare Technologies’ shares jumped 12% in early trade on Thursday following impressive Q4 FY25 earnings. As of 9:23 AM, the shares were trading 11.57% higher at Rs 858.20.
The company reported a 21% year-on-year (YoY) rise in revenue from operations to ₹187.2 crore, up from ₹154.2 crore in Q4 FY24. Gross margin rose 28% YoY to ₹137.7 crore, while normalized EBITDA (before ESOP) surged 78% YoY to ₹65.3 crore. Reported EBITDA climbed 70% YoY to ₹57.4 crore.
Net profit excluding exceptional items jumped 88% YoY to ₹32.5 crore. Including exceptionals, PAT stood at ₹21.3 crore, up 24% YoY. The company reported a healthy normalized EBITDA margin of 35% and a PAT margin (excluding exceptionals) of 17%.
For the full year FY25, Thyrocare posted a 20% revenue growth to ₹687.3 crore. Normalized EBITDA rose 37% to ₹209.9 crore, while net profit excluding exceptional items grew 45% YoY to ₹101.2 crore.
Operationally, Thyrocare recorded its highest-ever annual test volume at 167.9 million. It expanded its footprint by opening new labs in Bhagalpur and Kashmir. The company ended FY25 with a robust cash reserve of ₹191.8 crore, reinforcing its financial strength.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
